open access

Ahead of Print
Original article
Published online: 2020-07-08
Submitted: 2020-06-17
Accepted: 2020-07-01
Get Citation

Febuxostat ameliorates methotrexate-induced lung damage

S. M. Zaki, G. H.A. Hussein, H. M.A. Khalil, W. A. Abd Algaleel
DOI: 10.5603/FM.a2020.0075
·
Pubmed: 32644182

open access

Ahead of Print
ORIGINAL ARTICLES
Published online: 2020-07-08
Submitted: 2020-06-17
Accepted: 2020-07-01

Abstract

Background: The intention of the present study was to study the structural affection of the lung following Methotrexate (MTX) overdose. The proposed underlying mechanisms involved in lung affection were studied. The possible modulation role of febuxostat over such affection was studied.  

Materials and methods: 24 rats were divided into three groups: control, MTX-treated, febuxostat-treated. The study was continued for 2 weeks. Lung was processed for histological and immunohistochemical {Inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2)} studies. Inflammatory markers (TNF-α, IL-1), Western blot evaluation of NF-κB and oxidative/antioxidative markers were done.

Results: MTX-treated group exhibited inflammatory cellular infiltrations, thickened interalveolar septa, dilated congested blood vessels, extravasated blood, and apoptosis. The collagen fibers content increased 3-fold. MTX induced lung affection through oxidative stress (increase MDA /decrease GSH, SOD) and apoptosis. It induced sterile inflammation through increase NF-κB (two -fold), IL-1 (three-fold) and TNF-α (three-fold), COX-2 cells (2 ½-fold) and iNOS (6-fold).  With the use of febuxostat, the normal lung architecture was observed with a pit thickened interalveolar septum and extravasated blood. The collagen fibres content was minimal. Decrement of oxidative stress and sterile inflammation (COX-2 cells and iNOS were comparable to the control group. NF-κB, IL-1 and TNF-α became higher by 34, 64% and 100%).

Conclusions: The overdose of MTX displays inflammatory lung affection with residual fibrosis. It induces lung affection through oxidative stress, apoptosis and sterile inflammation. With the use of febuxostat, the normal lung architecture was preserved with a little structural affection or fibrotic residue. Febuxostat exerts its lung protection through its anti-inflammatory and antioxidant features.

Abstract

Background: The intention of the present study was to study the structural affection of the lung following Methotrexate (MTX) overdose. The proposed underlying mechanisms involved in lung affection were studied. The possible modulation role of febuxostat over such affection was studied.  

Materials and methods: 24 rats were divided into three groups: control, MTX-treated, febuxostat-treated. The study was continued for 2 weeks. Lung was processed for histological and immunohistochemical {Inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2)} studies. Inflammatory markers (TNF-α, IL-1), Western blot evaluation of NF-κB and oxidative/antioxidative markers were done.

Results: MTX-treated group exhibited inflammatory cellular infiltrations, thickened interalveolar septa, dilated congested blood vessels, extravasated blood, and apoptosis. The collagen fibers content increased 3-fold. MTX induced lung affection through oxidative stress (increase MDA /decrease GSH, SOD) and apoptosis. It induced sterile inflammation through increase NF-κB (two -fold), IL-1 (three-fold) and TNF-α (three-fold), COX-2 cells (2 ½-fold) and iNOS (6-fold).  With the use of febuxostat, the normal lung architecture was observed with a pit thickened interalveolar septum and extravasated blood. The collagen fibres content was minimal. Decrement of oxidative stress and sterile inflammation (COX-2 cells and iNOS were comparable to the control group. NF-κB, IL-1 and TNF-α became higher by 34, 64% and 100%).

Conclusions: The overdose of MTX displays inflammatory lung affection with residual fibrosis. It induces lung affection through oxidative stress, apoptosis and sterile inflammation. With the use of febuxostat, the normal lung architecture was preserved with a little structural affection or fibrotic residue. Febuxostat exerts its lung protection through its anti-inflammatory and antioxidant features.

Get Citation

Keywords

febuxostat, methotrexate, lung

About this article
Title

Febuxostat ameliorates methotrexate-induced lung damage

Journal

Folia Morphologica

Issue

Ahead of Print

Article type

Original article

Published online

2020-07-08

DOI

10.5603/FM.a2020.0075

Pubmed

32644182

Keywords

febuxostat
methotrexate
lung

Authors

S. M. Zaki
G. H.A. Hussein
H. M.A. Khalil
W. A. Abd Algaleel

References (38)
  1. Alamir I, Boukhettala N, Aziz M, et al. Beneficial effects of cathepsin inhibition to prevent chemotherapy-induced intestinal mucositis. Clin Exp Immunol. 2010; 162(2): 298–305.
  2. Arpag H, Gül M, Aydemir Y, et al. Protective effects of alpha-lipoic acid on methotrexate-induced oxidative lung injury in rats. J Invest Surg. 2018; 31(2): 107–113.
  3. Atuğ Özcan SS, Ceylan I, Ozcan E, et al. Evaluation of oxidative stress biomarkers in patients with fixed orthodontic appliances. Dis Markers. 2014; 2014: 597892.
  4. Barrera P, Laan RF, van Riel PL, et al. Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis. 1994; 53(7): 434–439.
  5. Birben E, Sahiner UM, Sackesen C, et al. Oxidative stress and antioxidant defense. World Allergy Organ J. 2012; 5(1): 9–19.
  6. Boukhettala N, Leblond J, Claeyssens S, et al. Methotrexate induces intestinal mucositis and alters gut protein metabolism independently of reduced food intake. Am J Physiol Endocrinol Metab. 2009; 296(1): E182–E190.
  7. Bourin M, Hascoët M. The mouse light/dark box test. Eur J Pharmacol. 2003; 463(1-3): 55–65.
  8. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72(1-2): 248–254.
  9. Carson C, Cannon G, Egger M, et al. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum. 1987; 16(3): 186–195.
  10. Charan J, Biswas T. How to calculate sample size for different study designs in medical research? Indian J Psychol Med. 2013; 35(2): 121–126.
  11. Conway R, Low C, Coughlan RJ, et al. Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials. BMJ. 2015; 350: h1269.
  12. Dhouib H, Jallouli M, Draief M, et al. Oxidative damage and histopathological changes in lung of rat chronically exposed to nicotine alone or associated to ethanol. Pathol Biol (Paris). 2015; 63(6): 258–267.
  13. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis. 2010; 4(1): 28–62.
  14. Elens I, Dekeyster E, Moons L. Methotrexate affects cerebrospinal fluid folate and tau levels and induces late cognitive deficits in mice. Neuroscience. 2019; 404: 62–70.
  15. Fahmi AN, Shehatou GS, Shebl AM. Febuxostat protects rats against lipopolysaccharide-induced lung inflammation in a dose-dependent manner, Naunyn Schmiedebergs. Arch Pharmacol, 389(3), pp. 2016; 389(3): 269–278.
  16. Festing MF, Altman DG. Guidelines for the design and statistical analysis of experiments using laboratory animals. ILAR J, 43(4), pp. 2002; 43(4): 244–258.
  17. François M, Takagi K, Legrand R, et al. Increased ghrelin but low ghrelin-reactive immunoglobulins in a rat model of methotrexate chemotherapy-induced anorexia. Front Nutr. 2016; 3: 23.
  18. Fukunaga K, Kohli P, Bonnans C, et al. Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J Immunol. 2005; 174(8): 5033–5039.
  19. Huang C, Hsu P, Hung Y, et al. Ornithine decarboxylase prevents methotrexate-induced apoptosis by reducing intracellular reactive oxygen species production. Apoptosis, 10(4), pp. 2005; 10(4): 895–907.
  20. Karve AV, Jagtiani S, Chitnis KSA. Evaluation of effect of allopurinol and febuxostat in behavioral model of depression in mice , Indian. J Pharmacol. 2013; 45(3): 244–247.
  21. Kurt A, Tumkaya L, Turut H, et al. Protective Effects of Infliximab on Lung Injury Induced by Methotrexate. Arch Bronconeumol. 2015; 51(11): 551–557.
  22. Leblond J, Le Pessot F, Hubert-Buron A, et al. Chemotherapy-induced mucositis is associated with changes in proteolytic pathways. Exp Biol Med (Maywood). 2008; 233(2): 219–228.
  23. Misra H, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem. 1972; 247(10): 3170–3175.
  24. Mohamed DI, Khairy E, Tawfek SS, et al. Coenzyme Q10 attenuates lung and liver fibrosis via modulation of autophagy in methotrexate treated rat. Biomed Pharmacother. 2019; 109: 892–901.
  25. Nair MP, Mahajan S, Reynolds JL, et al. The flavonoid quercetin inhibits proinflammatory cytokine (tumor necrosis factor alpha) gene expression in normal peripheral blood mononuclear cells via modulation of the NF-kappa beta system. Clin Vaccine Immunol. 2006; 13(3): 319–328.
  26. Ohbayashi M, Kubota S, Kawase A, et al. Involvement of epithelial-mesenchymal transition in methotrexate-induced pulmonary fibrosis. J Toxicol Sci. 2014; 39(2): 319–330.
  27. Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006; 58(1): 87–114.
  28. Pui CH, Pei D, Pappo AS, et al. Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children's Research Hospital, 1992 through 2007. J Clin Oncol. 2012; 30(16): 2005–2012.
  29. Rahman I, Kode A, Biswas SK. Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc. 2006; 1(6): 3159–3165.
  30. Ramos-Vara JA, Kiupel M, Baszler T. Suggested guidelines for immunohistochemical techniques in veterinary diagnostic laboratories. J Vet Diagn Invest. 2008; 20(4): 393–413.
  31. Robinson PC, Dalbeth N. Febuxostat for the treatment of hyperuricaemia in gout. Expert Opin Pharmacother. 2018; 19(11): 1289–1299.
  32. Sakthiswary R, Suresh E. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Lupus. 2014; 23(3): 225–235.
  33. Sathi N, Chikura B, Kaushik VV, et al. How common is methotrexate pneumonitis? A large prospective study investigates. Clin Rheumatol. 2012; 31(1): 79–83.
  34. Sivalingam VN, Duncan WC, Kirk E, et al. Diagnosis and management of ectopic pregnancy. J Fam Plann Reprod Health Care. 2011; 37(4): 231–240.
  35. Suvarna SK, Layton C, Bancroft JD. Bancroft's theory and practice of histological techniques. Eighth edition. Oxford, Elsevier 2019.
  36. Tsuda H, Kawada N, Kaimori Jy, et al. Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress. Biochem Biophys Res Commun. 2012; 427(2): 266–272.
  37. Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc. 2007; 2(2): 322–328.
  38. Zhu H, Deng FY, Mo XB, et al. Pharmacogenetics and pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the 2013 update. Pharmacogenomics. 2014; 15(4): 551–566.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By  "Via Medica sp. z o.o." sp.k., Świętokrzyska 73, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl